Anticoagulation in atrial fibrillation: NOAC prescribing in primary health care

PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study)

(2015) Ozcan Basaran et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

(2015) N. S. Abraham et al.   BMJ-British Medical Journal

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

(2015) N. S. Abraham et al.   BMJ-British Medical Journal

Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation

(2014) Anne-Sophie Larock et al.   ANNALS OF PHARMACOTHERAPY

Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs

(2013) Amelia Troncoso et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century

(2013) Jocasta Ball et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST